<DOC>
	<DOCNO>NCT01932801</DOCNO>
	<brief_summary>The goal study test efficacy extended-release naltrexone harm reduction counsel reduce alcohol-related harm among homeless people alcohol dependence .</brief_summary>
	<brief_title>Harm Reduction With Pharmacotherapy ( HaRP )</brief_title>
	<detailed_description>Homelessness alcohol dependence commonly co-occurring serious public health issue . Unfortunately , abstinence-based alcohol treatment approach minimally effective engage successfully treat homeless individual alcohol dependence . There therefore call flexible client-centered approach tailor population 's need . Innovative , low-barrier approach ( e.g. , Housing First alcohol management program ) apply population efficacious reduce alcohol use relate problem well utilization publicly fund service associate cost . Such approach refer harm-reduction intervention focus reduce alcohol-related harm affect individual community without require commitment abstinence-based goal . Although psychosocial , harm-reduction approach begin proliferate population , pharmacological counterpart support enhance effort . One medication could address treatment gap extended-release naltrexone ( XR-NTX ; market Vivitrol® ) . XR-NTX 30-day , extended release formulation opioid receptor antagonist , naltrexone , administer monthly via gluteal intramuscular injection . The propose Phase II study feature four-arm RCT ( N=300 ) design test efficacy XR-NTX pharmacological adjunct exist psychosocial harm-reduction service provide community agency homeless people alcohol dependence . The propose study include 24-week follow-up test relative efficacy 3 active treatment combinations—1 ) XR-NTX+harm reduction counseling , 2 ) placebo+harm reduction counsel 3 ) harm reduction counseling ( HRC ) —compared service usual ( TAU ) participant receive community agency . This propose design allow u dismantle active treatment component thereby detect potential `` placebo effect '' administration injection attention medical professional . In study , three primary specific aim . First , test relative efficacy XR-NTX , placebo HRC compare TAU decrease alcohol quantity , frequency alcohol-related problem . Second , test hypothesize mediator intervention effect . Specifically , hypothesize active treatment precipitate increase motivation change decrease craving , , turn , mediate active treatment effect alcohol outcomes . Finally , test treatment effect publicly funded service cost ( i.e. , emergency medical service , ER visit , hospital admission , county jail ) . It hypothesize XR-NTX , placebo HRC group show great decrease publicly funded service cost TAU group .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<criteria>register client one name partner site least 21 year age ( legal reason ) agree use adequate form birth control ( female childbearing year ) fulfil criterion current alcohol dependence accord DSMIVTR criterion determine SCIDI/P refusal inability consent participation research constitute risk safety security client staff know sensitivity allergy naltrexone/XRNTX current treatment naltrexone/XRNTX pregnant nursing suicide attempt within past year renal insufficiency/serum creatinine level &gt; 1.5 current opioid dependence accord DSMIVTR criterion liver transaminase ( AST , ALT ) &gt; 5 time upper limit normal ( ULN ) clinical diagnosis decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>harm reduction , naltrexone , alcohol dependence , homelessness</keyword>
</DOC>